- ICH GCP
- Rejestr badań klinicznych w USA
- Badanie kliniczne NCT00676052
Dose-Ranging Study Of GSK233705B In Subjects With Chronic Obstructive Pulmonary Disease (COPD)
Multicentre Dose Ranging Study for Once Daily GSK233705 in COPD
Przegląd badań
Status
Typ studiów
Zapisy (Rzeczywisty)
Faza
- Faza 2
Kontakty i lokalizacje
Lokalizacje studiów
-
-
-
Bellville, Afryka Południowa, 7531
- GSK Investigational Site
-
Mowbray, Afryka Południowa, 7700
- GSK Investigational Site
-
-
Gauteng
-
Cape Town, Gauteng, Afryka Południowa, 7505
- GSK Investigational Site
-
Mueckelneck, Gauteng, Afryka Południowa, 0001
- GSK Investigational Site
-
Parktown, Gauteng, Afryka Południowa, 2193
- GSK Investigational Site
-
-
-
-
-
Tucuman, Argentyna, 4000
- GSK Investigational Site
-
-
Buenos Aires
-
La Plata, Buenos Aires, Argentyna, CP1900
- GSK Investigational Site
-
Mar del Plata, Buenos Aires, Argentyna, B7600FZN
- GSK Investigational Site
-
Mar del Plata, Buenos Aires, Argentyna, 7600
- GSK Investigational Site
-
Pergamino, Buenos Aires, Argentyna, 2700
- GSK Investigational Site
-
-
-
-
-
Dimitrovgrad, Bułgaria, 6400
- GSK Investigational Site
-
Ruse, Bułgaria, 7000
- GSK Investigational Site
-
Sofia, Bułgaria, 1431
- GSK Investigational Site
-
Sofia, Bułgaria
- GSK Investigational Site
-
-
-
-
-
Santiago, Chile, 8380453
- GSK Investigational Site
-
-
Región Metro De Santiago
-
Santiago, Región Metro De Santiago, Chile, 7500551
- GSK Investigational Site
-
Santiago, Región Metro De Santiago, Chile
- GSK Investigational Site
-
Santiago, Región Metro De Santiago, Chile, 7500691
- GSK Investigational Site
-
-
Valparaíso
-
Valparaiso, Valparaíso, Chile, 2341131
- GSK Investigational Site
-
-
-
-
-
Cavite, Filipiny, 4114
- GSK Investigational Site
-
Quezon City, Filipiny, 1100
- GSK Investigational Site
-
Quezon City, Filipiny, 1109
- GSK Investigational Site
-
-
-
-
-
Almelo, Holandia, 7609 PP
- GSK Investigational Site
-
Eindhoven, Holandia, 5623 EJ
- GSK Investigational Site
-
Hoofddorp, Holandia, 2134 TM
- GSK Investigational Site
-
Hoorn, Holandia, 1624 NP
- GSK Investigational Site
-
-
-
-
Alberta
-
Calgary, Alberta, Kanada, T2N 4N1
- GSK Investigational Site
-
-
Newfoundland and Labrador
-
Bay Roberts, Newfoundland and Labrador, Kanada, A0A 1G0
- GSK Investigational Site
-
-
Ontario
-
Mississauga, Ontario, Kanada, L5A 3V4
- GSK Investigational Site
-
Ottawa, Ontario, Kanada, K1H 8L6
- GSK Investigational Site
-
Toronto, Ontario, Kanada, M5G 1N8
- GSK Investigational Site
-
-
Quebec
-
Saint Romuald, Quebec, Kanada, G6W 5M6
- GSK Investigational Site
-
Sainte Jerome, Quebec, Kanada, J7Z 5T3
- GSK Investigational Site
-
Sainte-Foy, Quebec, Kanada, G1V 4G5
- GSK Investigational Site
-
-
-
-
-
Berlin, Niemcy, 14057
- GSK Investigational Site
-
Berlin, Niemcy, 10117
- GSK Investigational Site
-
Berlin, Niemcy, 10717
- GSK Investigational Site
-
Berlin, Niemcy, 10787
- GSK Investigational Site
-
Berlin, Niemcy, 10559
- GSK Investigational Site
-
-
Baden-Wuerttemberg
-
Wiesloch, Baden-Wuerttemberg, Niemcy, 69168
- GSK Investigational Site
-
-
Hessen
-
Gelnhausen, Hessen, Niemcy, 63571
- GSK Investigational Site
-
-
Niedersachsen
-
Hannover, Niedersachsen, Niemcy, 30159
- GSK Investigational Site
-
Hannover, Niedersachsen, Niemcy, 30167
- GSK Investigational Site
-
-
Sachsen
-
Dresden, Sachsen, Niemcy, 01307
- GSK Investigational Site
-
-
Sachsen-Anhalt
-
Magdeburg, Sachsen-Anhalt, Niemcy, 39112
- GSK Investigational Site
-
-
Schleswig-Holstein
-
Luebeck, Schleswig-Holstein, Niemcy, 23552
- GSK Investigational Site
-
-
Thueringen
-
Schmoelln, Thueringen, Niemcy, 04626
- GSK Investigational Site
-
-
-
-
-
Seoul, Republika Korei, 152-703
- GSK Investigational Site
-
Seoul, Republika Korei, 133--792
- GSK Investigational Site
-
-
-
-
-
Brasov, Rumunia, 500112
- GSK Investigational Site
-
Bucharest, Rumunia, 020125
- GSK Investigational Site
-
Iasi, Rumunia, 700115
- GSK Investigational Site
-
-
-
-
Alabama
-
Jasper, Alabama, Stany Zjednoczone, 35501
- GSK Investigational Site
-
-
Arizona
-
Glendale, Arizona, Stany Zjednoczone, 85306
- GSK Investigational Site
-
-
California
-
Fountain Valley, California, Stany Zjednoczone, 92708
- GSK Investigational Site
-
Fullerton, California, Stany Zjednoczone, 92835
- GSK Investigational Site
-
Los Angeles, California, Stany Zjednoczone, 90095
- GSK Investigational Site
-
Los Angeles, California, Stany Zjednoczone, 90048
- GSK Investigational Site
-
Riverside, California, Stany Zjednoczone, 92506
- GSK Investigational Site
-
Roseville, California, Stany Zjednoczone, 95661
- GSK Investigational Site
-
San Diego, California, Stany Zjednoczone, 92103-8415
- GSK Investigational Site
-
-
Florida
-
Brandon, Florida, Stany Zjednoczone, 33511
- GSK Investigational Site
-
Panama City, Florida, Stany Zjednoczone, 32405
- GSK Investigational Site
-
South Miami, Florida, Stany Zjednoczone, 33143
- GSK Investigational Site
-
-
Idaho
-
Coeur d'Alene, Idaho, Stany Zjednoczone, 83814
- GSK Investigational Site
-
-
Kentucky
-
Madisonville, Kentucky, Stany Zjednoczone, 42431
- GSK Investigational Site
-
-
Louisiana
-
Lafayette, Louisiana, Stany Zjednoczone, 70503
- GSK Investigational Site
-
Sunset, Louisiana, Stany Zjednoczone, 70584
- GSK Investigational Site
-
-
Missouri
-
Saint Charles, Missouri, Stany Zjednoczone, 63301
- GSK Investigational Site
-
-
North Carolina
-
Charlotte, North Carolina, Stany Zjednoczone, 28207
- GSK Investigational Site
-
-
South Carolina
-
Charleston, South Carolina, Stany Zjednoczone, 29406-7108
- GSK Investigational Site
-
Greenville, South Carolina, Stany Zjednoczone, 29615
- GSK Investigational Site
-
Spartanburg, South Carolina, Stany Zjednoczone, 29303
- GSK Investigational Site
-
Union, South Carolina, Stany Zjednoczone, 29379
- GSK Investigational Site
-
-
Texas
-
Houston, Texas, Stany Zjednoczone, 77030
- GSK Investigational Site
-
-
Virginia
-
Abingdon, Virginia, Stany Zjednoczone, 24210
- GSK Investigational Site
-
Richmond, Virginia, Stany Zjednoczone, 23229
- GSK Investigational Site
-
-
-
-
-
Bangkok, Tajlandia, 10700
- GSK Investigational Site
-
Chiangmai, Tajlandia, 50200
- GSK Investigational Site
-
Khon Kaen, Tajlandia, 40002
- GSK Investigational Site
-
Songkla, Tajlandia, 90110
- GSK Investigational Site
-
-
-
-
-
Balassagyarmat, Węgry, 2660
- GSK Investigational Site
-
Budapest, Węgry, 1095
- GSK Investigational Site
-
Budapest, Węgry, H-1529
- GSK Investigational Site
-
Mátraháza, Węgry, 3233
- GSK Investigational Site
-
-
-
-
-
London, Zjednoczone Królestwo, SE5 9PJ
- GSK Investigational Site
-
Norwich, Zjednoczone Królestwo, NR4 7UY
- GSK Investigational Site
-
-
Sussex East
-
Brighton, Sussex East, Zjednoczone Królestwo, BN2 5BE
- GSK Investigational Site
-
-
Kryteria uczestnictwa
Kryteria kwalifikacji
Wiek uprawniający do nauki
Akceptuje zdrowych ochotników
Płeć kwalifikująca się do nauki
Opis
Inclusion Criteria:
- A signed and dated written informed consent prior to study participation.
- Male or female adults.
A female is eligible to enter and participate in this study if she is of:
non-childbearing potential (i.e., physiologically incapable of becoming pregnant), including any female who is post-menopausal; or child-bearing potential, has a negative pregnancy test at Visit 1/Visit 1A, and agrees to one of the protocol-specified acceptable contraceptive methods used consistently and correctly (i.e. according to the approved product label and the instructions of the physician for the duration of the study - Screening through follow-up contact)
- 40 to 80 years of age at Visit 1
- An established clinical history of COPD
- Current or previous cigarette smokers with a history of cigarette smoking of ≥ 10 pack-years 1.
- A post-albuterol/salbutamol FEV1/FVC ratio of ≤0.70 and a post-albuterol/salbutamol FEV1 of ≥35 and ≤70% of predicted normal values
Exclusion Criteria:
Subjects meeting any of the following criteria must not be enrolled in the study:
- Women who are pregnant or lactating.
- A current diagnosis of asthma.
- Known respiratory disorders other than COPD including but not limited to α-1 antitrypsin deficiency as the underlying cause of COPD, active tuberculosis, lung cancer, bronchiectasis, sarcoidosis, lung fibrosis, pulmonary hypertension, and interstitial lung disease.
- Any previous lung resection surgery (e.g., lung volume reduction surgery or lobectomy)
- Clinically significant Chest X-ray or computed tomography (CT) scan abnormalities within 6 months prior to Visit 1 that are not believed to be due to COPD.
- Use of oral corticosteroids or antibiotics for COPD within 6 weeks prior to Visit 1.
- Hospitalization for COPD or pneumonia within 3 months prior to Visit 1.
- Use of antibiotics for a lower respiratory tract infection within 30 days prior to Visit 1.
- Clinically significant and uncontrolled cardiovascular, neurological, psychiatric, renal, gastro-intestinal, immunological, endocrine (including uncontrolled diabetes or thyroid disease) or hematological abnormalities.
- An abnormal and clinically significant 12-lead electrocardiogram (ECG) that results in active medical problem.
- Positive for Hepatitis B or Hepatitis C at Visit 1.
- A current malignancy or previous history of cancer in remission for <5 years prior to Visit 1
- A history of allergy or hypersensitivity to ipratropium, tiotropium, or atropine and any of their derivatives, lactose/milk protein or magnesium stearate.
- Medical diagnosis of narrow-angle glaucoma, prostatic hypertrophy or bladder neck obstruction that in the opinion of the study investigator would prevent use of an inhaled anticholingeric.
- Medically unable to withhold albuterol/salbutamol for 6 hours prior to spirometry testing at each study visit or to withhold ipratropium (if applicable) for the 6-hour period prior to the first 3 study visits (ipratropium cannot be used after Visit 3).
- Additional Medications: Unable to stop using certain medications such as bronchodilators and corticosteroids for the protocol-specified times prior to Visit 1 (the Investigator will discuss the specific medications)
- Use of inhaled corticosteroids at a dose greater than 1000 mcg/day of fluticasone propionate or equivalent within 30 days prior to Visit 1.
- Use of long-term oxygen therapy (LTOT) or supplemental oxygen required for greater than 12 hours a day. Oxygen use as needed is not exclusionary.
- Clinically significant sleep apnea that requires continuous positive airway pressure (CPAP)
- Use of regular nebulized therapy
- Use of nocturnal positive pressure or non-invasive positive pressure ventilation (NIPPV)
- Participation in the acute phase of a pulmonary rehabilitation program within 4 weeks prior to Visit 1.
- An investigator, sub-investigator, study coordinator, employee of a participating investigator or study site, or immediate family member of the above who is involved in this study
- History of psychiatric disease, intellectual deficiency, poor motivation, substance abuse in the two years prior to Visit 1 (including drug and alcohol), or other conditions, which will limit the validity of informed consent to participate in the study.
- Use of GSK233705B in previous studies.
Plan studiów
Jak projektuje się badanie?
Szczegóły projektu
- Główny cel: Leczenie
- Przydział: Randomizowane
- Model interwencyjny: Przydział równoległy
- Maskowanie: Podwójnie
Broń i interwencje
Grupa uczestników / Arm |
Interwencja / Leczenie |
---|---|
Eksperymentalny: Arm 1
GSK233705 12.5mcg
|
Once daily via dry powder inhaler
|
Eksperymentalny: Arm 2
GSK233705 25mcg
|
once daily via dry powder inhaler
|
Eksperymentalny: Arm 3
GSK233705 50mcg
|
Once daily via dry powder inhaler
|
Eksperymentalny: Arm 4
GSK233705 100mcg
|
Once daily via dry powder inhaler
|
Eksperymentalny: Arm 5
GSK233705 200mcg
|
Once daily via dry powder inhaler
|
Komparator placebo: Arm 6
Placebo
|
Once daily via dry powder imhaler
|
Co mierzy badanie?
Podstawowe miary wyniku
Miara wyniku |
Opis środka |
Ramy czasowe |
---|---|---|
Change From Baseline in Trough Forced Expiratory Volume in 1 Second (FEV1) at Day 29
Ramy czasowe: Baseline (pre-dose Day 1) and Day 29
|
The trough FEV1 is defined as the mean of the FEV1 values obtained 23 and 24 hours after dosing on Day 28.
The Baseline FEV1 is the mean of the two assessments made 30 minutes pre-dose and immediately pre-dose [time 0] on Day 1. Change from Baseline was calculated by subtracting the post-baseline assessment value from the Baseline value.
|
Baseline (pre-dose Day 1) and Day 29
|
Miary wyników drugorzędnych
Miara wyniku |
Opis środka |
Ramy czasowe |
---|---|---|
Change From Baseline in Weighted Mean for 0 to 24 Hours Serial FEV1 on Day 1 to 2 and 28 to 29
Ramy czasowe: Baseline (pre-dose Day 1) and Days 1 to 2, Days 28 to 29
|
Weighted means serial FEV1 was derived by calculating the area under curve (AUC), and then dividing by the time interval over which the AUC was calculated.
Baseline was defined at pre-dose Day 1.
The weighted mean change from Baseline is the weighted mean minus Baseline.
The AUC was calculated using the trapezoidal rule.
For all post-dose observations, actual times that the spirometry measurements were conducted was used for the calculation.
Pre-dose observations were counted as 0 hr observations - that is they had their time set to the time of dosing.
The pre-dose value used for the calculation of the AUC was the mean of the two pre-dose observations (-30 and 0 min for Day 1 or 28).
If one of these observations was missing, the remaining single pre-dose observation was used.
|
Baseline (pre-dose Day 1) and Days 1 to 2, Days 28 to 29
|
Change From Baseline in Weighted Mean for 0 to 24 Hours Forced Vital Capacity (FVC) on Day 1 to 2 and 28 to 29
Ramy czasowe: Baseline (pre-dose Day 1) and Days 1 to 2, Days 28 to 29
|
Weighted means serial FVC was derived by calculating the AUC, and then dividing by the time interval over which the AUC was calculated.
Baseline was defined at pre-dose Day 1.
The weighted mean change from Baseline is the weighted mean minus Baseline.
The AUC was calculated using the trapezoidal rule.
For all post-dose observations, actual times that the spirometry measurements were conducted was used for the calculation.
Pre-dose observations were counted as 0 hr observations - that is they had their time set to the time of dosing.
The pre-dose value used for the calculation of the AUC was the mean of the two pre-dose observations (-30 and 0 min for Day 1 or 28).
If one of these observations was missing, the remaining single pre-dose observation was used.
|
Baseline (pre-dose Day 1) and Days 1 to 2, Days 28 to 29
|
Change From Baseline in Clinic Visit Trough FVC on Day 29
Ramy czasowe: Baseline (pre-dose Day 1) and Day 29
|
The trough FVC is defined as the mean of the FVC values obtained 23 and 24 hours after dosing on Day 28.
The Baseline FVC is the mean of the two assessments made 30 minutes pre-dose and immediately pre-dose [time 0] on Day 1. Change from Baseline was calculated by subtracting the post-baseline assessment value from the Baseline value.
|
Baseline (pre-dose Day 1) and Day 29
|
Współpracownicy i badacze
Sponsor
Publikacje i pomocne linki
Daty zapisu na studia
Główne daty studiów
Rozpoczęcie studiów (Rzeczywisty)
Zakończenie podstawowe (Rzeczywisty)
Ukończenie studiów (Rzeczywisty)
Daty rejestracji na studia
Pierwszy przesłany
Pierwszy przesłany, który spełnia kryteria kontroli jakości
Pierwszy wysłany (Oszacować)
Aktualizacje rekordów badań
Ostatnia wysłana aktualizacja (Rzeczywisty)
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
Ostatnia weryfikacja
Więcej informacji
Terminy związane z tym badaniem
Słowa kluczowe
Dodatkowe istotne warunki MeSH
Inne numery identyfikacyjne badania
- AC2110664
Plan dla danych uczestnika indywidualnego (IPD)
Planujesz udostępniać dane poszczególnych uczestników (IPD)?
Opis planu IPD
Badanie danych/dokumentów
-
Formularz zgłoszenia przypadku z adnotacjami
Identyfikator informacji: AC2110664Komentarze do informacji: For additional information about this study please refer to the GSK Clinical Study Register
-
Protokół badania
Identyfikator informacji: AC2110664Komentarze do informacji: For additional information about this study please refer to the GSK Clinical Study Register
-
Raport z badania klinicznego
Identyfikator informacji: AC2110664Komentarze do informacji: For additional information about this study please refer to the GSK Clinical Study Register
-
Plan analizy statystycznej
Identyfikator informacji: AC2110664Komentarze do informacji: For additional information about this study please refer to the GSK Clinical Study Register
-
Indywidualny zestaw danych uczestnika
Identyfikator informacji: AC2110664Komentarze do informacji: For additional information about this study please refer to the GSK Clinical Study Register
-
Specyfikacja zestawu danych
Identyfikator informacji: AC2110664Komentarze do informacji: For additional information about this study please refer to the GSK Clinical Study Register
-
Formularz świadomej zgody
Identyfikator informacji: AC2110664Komentarze do informacji: For additional information about this study please refer to the GSK Clinical Study Register
Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .
Badania kliniczne na Choroba płuc, przewlekła obturacja
-
Spero TherapeuticsZakończonyKompleks Mycobacterium Avium | Niegruźlicze Mycobacterium Pulmonary DiseaseStany Zjednoczone
Badania kliniczne na GSK233705 12.5mcg
-
GlaxoSmithKlineZakończonyChoroba płuc, przewlekła obturacjaStany Zjednoczone
-
GlaxoSmithKlineZakończony
-
GlaxoSmithKlineZakończonyChoroba płuc, przewlekła obturacjaBelgia, Szwecja
-
GlaxoSmithKlineZakończonyChoroba płuc, przewlekła obturacjaZjednoczone Królestwo
-
GlaxoSmithKlineZakończonyChoroba płuc, przewlekła obturacjaZjednoczone Królestwo
-
GlaxoSmithKlineZakończonyChoroba płuc, przewlekła obturacjaNiemcy
-
GlaxoSmithKlineZakończonyChoroba płuc, przewlekła obturacjaNiemcy, Holandia, Finlandia, Federacja Rosyjska, Zjednoczone Królestwo